Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2015-06-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
关于使用募集资金置换预先已投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the use of raised funds to replace self-raised funds previously invested in projects. It includes details about the fundraising, approvals by the board, supervisory opinions, independent directors' opinions, and auditor verification. The document references regulatory compliance with the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is not a full financial report but a specific announcement about capital usage and compliance. The document length is 3449 characters, which is relatively short and focused on a capital/financing update rather than a full report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2015-06-24 Chinese
独立董事关于第二届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding the use of raised funds and cash management related to a company's board meeting. It references compliance with laws and regulations, and audit confirmation by an accounting firm. The content focuses on governance and financial oversight matters related to the board's decisions, rather than presenting full financial statements or detailed financial results. The document length is short (959 characters) and it is a formal opinion related to board matters, not a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions.
2015-06-24 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the company's policies, principles, responsibilities, and procedures for managing investor relations, including communication methods, roles of management and departments, and compliance with laws and regulations. It is a governance-related document focusing on internal rules and practices for investor relations management rather than a financial report, earnings release, or announcement. It does not contain financial statements or data, nor is it a report publication announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2015-06-24 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by the company 普莱柯生物工程股份有限公司. It details the stock price drop over three consecutive trading days exceeding 20%, confirms no undisclosed material information, and provides risk warnings. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement related to stock price movement and compliance with stock exchange rules, not a financial report or earnings release. The document length is short (999 characters) and it serves as a formal disclosure to the market about stock price abnormality and company confirmation of no undisclosed material events. This fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-06-16 Chinese
控股股东及实际控制人关于回复股票异常波动有关情况的函
Regulatory Filings
2015-06-16 Chinese
关于回复生物工程股份有限公司了解股票异常波动有关情况的函
Regulatory Filings
2015-06-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.